Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.45 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3195109 | 0.84 | CHRM1 (0.46) | CHRNA7CHRM1CHRM2 | |
| SCHEMBL4198260 | 0.84 | USP30 (0.46) | CHRNA7CHRM1CHRM2CHRM3 | |
| SCHEMBL4205244 | 0.81 | NTMT1 (0.47) | CHRNA7NTMT1CHRM1CHRM2CHRM3 | |
| SCHEMBL4206234 | 0.81 | CHRM1 (0.45) | CHRNA7NTMT1CHRM1CHRM2CHRM3 | |
| SCHEMBL3840350 | 0.80 | CHRNA7 (0.44) | CHRNA7NTMT1CHRM1CHRM2CHRM3 | |
| SCHEMBL3840357 | 0.80 | CHRNA7 (0.44) | CHRNA7NTMT1CHRM1CHRM2CHRM3 | |
| SCHEMBL4201115 | 0.80 | NTMT1 (0.42) | CHRNA7NTMT1CHRM1CHRM2 | |
| SCHEMBL4205959 | 0.79 | CHRNA7 (0.43) | CHRNA7NTMT1CHRM1CHRM2CHRM3 | |
| SCHEMBL17004270 | 0.76 | PRKDC (0.33) | — | |
| SCHEMBL4202405 | 0.76 | CHRNA7 (0.59) | CHRNA7NTMT1CHRM1CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005390-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S | 2009-01-01 | — | — | US | claimed |
| EP-1532144-B1 | QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH AS (DK) | 2008-01-23 | — | — | EP | claimed |
| US-20050245567-A1 | Novel quinuclidine derivatives and their use | NEUROSEARCH A/S (DK) | 2005-11-03 | — | — | US | claimed |
| EP-1532144-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2005-05-25 | — | — | EP | claimed |
| WO-2004016608-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2004-02-26 | — | — | WO | claimed |
| US-20090005390-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S | 2009-01-01 | — | — | US | disclosed |
| EP-1905771-A2 | Quinuclidine derivatives and their use | NeuroSearch A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| EP-1532144-B1 | QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH AS (DK) | 2008-01-23 | — | — | EP | disclosed |
| US-20050245567-A1 | Novel quinuclidine derivatives and their use | NEUROSEARCH A/S (DK) | 2005-11-03 | — | — | US | disclosed |
| EP-1532144-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004016608-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005390-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | ACHE, CHRNA5, CHRNA3 | CHRNA7 9/4885NTMT1 1796/4885CHRM1 28/4885 |
| US-20050245567-A1 | Novel quinuclidine derivatives and their use | ACHE, CHRNA5, CHRNA3 | CHRNA7 9/4885NTMT1 1796/4885CHRM1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.